Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.
Identifieur interne : 000D63 ( Main/Exploration ); précédent : 000D62; suivant : 000D64Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.
Auteurs : Yan Zhou [États-Unis] ; Yuan Li [États-Unis] ; Hong-Min Ni [États-Unis] ; Wen-Xing Ding [États-Unis] ; Hua Zhong [République populaire de Chine]Source :
- Toxicology and applied pharmacology [ 1096-0333 ] ; 2016.
Descripteurs français
- KwdFr :
- Autophagie (physiologie), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (métabolisme), Facteur-2 apparenté à NF-E2 (métabolisme), Humains, Lignée cellulaire tumorale, Récepteurs ErbB (métabolisme), Survie cellulaire (physiologie), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (métabolisme).
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- métabolisme : Carcinome pulmonaire non à petites cellules, Facteur-2 apparenté à NF-E2, Récepteurs ErbB, Tumeurs du poumon.
- physiologie : Autophagie, Survie cellulaire.
- Humains, Lignée cellulaire tumorale.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : ErbB Receptors, NF-E2-Related Factor 2.
- metabolism : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- physiology : Autophagy, Cell Survival.
- Cell Line, Tumor, Humans.
Abstract
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Icotinib and Gefitinib are two epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that have been used to treat NSCLC. While it is well known that mutations of EGFR can affect the sensitivity of NSCLC to the EGFR-TKI, other mechanisms may also be adopted by lung cancer cells to develop resistance to EGFR-TKI treatment. Cancer cells can use multiple adaptive mechanisms such as activation of autophagy and Nrf2 to protect against various stresses and chemotherapeutic drugs. Whether autophagy or Nrf2 activation contributes to the resistance of NSCLC to EGFR-TKI treatment in wild-type EGFR NSCLC cells remains elusive. In the present study, we confirmed that Icotinib and Gefitinib induced apoptosis in EGFR mutant HCC827 but not in EGFR wild-type A549 NSCLC cells. Icotinib and Gefitinib did not induce autophagic flux or inhibit mTOR in A549 cells. Moreover, suppression of autophagy by chloroquine, a lysosomal inhibitor, did not affect Icotinib- or Gefitinib-induced cell death in A549 cells. In contrast, Brusatol, an Nrf2 inhibitor, significantly suppressed the cell survival of A549 cells. However, Brusatol did not further sensitize A549 cells to EGFR TKI-induced cell death. Results from this study suggest that inhibition of Nrf2 can decrease cell vitality of EGFR wild-type A549 cells independent of autophagy.
DOI: 10.1016/j.taap.2016.09.010
PubMed: 27639429
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000194
- to stream PubMed, to step Curation: 000194
- to stream PubMed, to step Checkpoint: 000198
- to stream Ncbi, to step Merge: 000357
- to stream Ncbi, to step Curation: 000357
- to stream Ncbi, to step Checkpoint: 000357
- to stream Main, to step Merge: 000D64
- to stream Main, to step Curation: 000D63
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.</title><author><name sortKey="Zhou, Yan" sort="Zhou, Yan" uniqKey="Zhou Y" first="Yan" last="Zhou">Yan Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Li, Yuan" sort="Li, Yuan" uniqKey="Li Y" first="Yuan" last="Li">Yuan Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Ni, Hong Min" sort="Ni, Hong Min" uniqKey="Ni H" first="Hong-Min" last="Ni">Hong-Min Ni</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Ding, Wen Xing" sort="Ding, Wen Xing" uniqKey="Ding W" first="Wen-Xing" last="Ding">Wen-Xing Ding</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Zhong, Hua" sort="Zhong, Hua" uniqKey="Zhong H" first="Hua" last="Zhong">Hua Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. Electronic address: eddiedong8@hotmail.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030</wicri:regionArea><wicri:noRegion>Shanghai 200030</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27639429</idno><idno type="pmid">27639429</idno><idno type="doi">10.1016/j.taap.2016.09.010</idno><idno type="wicri:Area/PubMed/Corpus">000194</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000194</idno><idno type="wicri:Area/PubMed/Curation">000194</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000194</idno><idno type="wicri:Area/PubMed/Checkpoint">000198</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000198</idno><idno type="wicri:Area/Ncbi/Merge">000357</idno><idno type="wicri:Area/Ncbi/Curation">000357</idno><idno type="wicri:Area/Ncbi/Checkpoint">000357</idno><idno type="wicri:Area/Main/Merge">000D64</idno><idno type="wicri:Area/Main/Curation">000D63</idno><idno type="wicri:Area/Main/Exploration">000D63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.</title><author><name sortKey="Zhou, Yan" sort="Zhou, Yan" uniqKey="Zhou Y" first="Yan" last="Zhou">Yan Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Li, Yuan" sort="Li, Yuan" uniqKey="Li Y" first="Yuan" last="Li">Yuan Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Ni, Hong Min" sort="Ni, Hong Min" uniqKey="Ni H" first="Hong-Min" last="Ni">Hong-Min Ni</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Ding, Wen Xing" sort="Ding, Wen Xing" uniqKey="Ding W" first="Wen-Xing" last="Ding">Wen-Xing Ding</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Zhong, Hua" sort="Zhong, Hua" uniqKey="Zhong H" first="Hua" last="Zhong">Hua Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. Electronic address: eddiedong8@hotmail.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030</wicri:regionArea><wicri:noRegion>Shanghai 200030</wicri:noRegion></affiliation></author></analytic><series><title level="j">Toxicology and applied pharmacology</title><idno type="eISSN">1096-0333</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autophagy (physiology)</term><term>Carcinoma, Non-Small-Cell Lung (metabolism)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Cell Line, Tumor</term><term>Cell Survival (physiology)</term><term>ErbB Receptors (metabolism)</term><term>Humans</term><term>Lung Neoplasms (metabolism)</term><term>Lung Neoplasms (pathology)</term><term>NF-E2-Related Factor 2 (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Autophagie (physiologie)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (métabolisme)</term><term>Facteur-2 apparenté à NF-E2 (métabolisme)</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Récepteurs ErbB (métabolisme)</term><term>Survie cellulaire (physiologie)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>ErbB Receptors</term><term>NF-E2-Related Factor 2</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Facteur-2 apparenté à NF-E2</term><term>Récepteurs ErbB</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Autophagie</term><term>Survie cellulaire</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Autophagy</term><term>Cell Survival</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Lignée cellulaire tumorale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Icotinib and Gefitinib are two epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that have been used to treat NSCLC. While it is well known that mutations of EGFR can affect the sensitivity of NSCLC to the EGFR-TKI, other mechanisms may also be adopted by lung cancer cells to develop resistance to EGFR-TKI treatment. Cancer cells can use multiple adaptive mechanisms such as activation of autophagy and Nrf2 to protect against various stresses and chemotherapeutic drugs. Whether autophagy or Nrf2 activation contributes to the resistance of NSCLC to EGFR-TKI treatment in wild-type EGFR NSCLC cells remains elusive. In the present study, we confirmed that Icotinib and Gefitinib induced apoptosis in EGFR mutant HCC827 but not in EGFR wild-type A549 NSCLC cells. Icotinib and Gefitinib did not induce autophagic flux or inhibit mTOR in A549 cells. Moreover, suppression of autophagy by chloroquine, a lysosomal inhibitor, did not affect Icotinib- or Gefitinib-induced cell death in A549 cells. In contrast, Brusatol, an Nrf2 inhibitor, significantly suppressed the cell survival of A549 cells. However, Brusatol did not further sensitize A549 cells to EGFR TKI-induced cell death. Results from this study suggest that inhibition of Nrf2 can decrease cell vitality of EGFR wild-type A549 cells independent of autophagy.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Kansas</li></region></list><tree><country name="États-Unis"><region name="Kansas"><name sortKey="Zhou, Yan" sort="Zhou, Yan" uniqKey="Zhou Y" first="Yan" last="Zhou">Yan Zhou</name></region><name sortKey="Ding, Wen Xing" sort="Ding, Wen Xing" uniqKey="Ding W" first="Wen-Xing" last="Ding">Wen-Xing Ding</name><name sortKey="Li, Yuan" sort="Li, Yuan" uniqKey="Li Y" first="Yuan" last="Li">Yuan Li</name><name sortKey="Ni, Hong Min" sort="Ni, Hong Min" uniqKey="Ni H" first="Hong-Min" last="Ni">Hong-Min Ni</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Zhong, Hua" sort="Zhong, Hua" uniqKey="Zhong H" first="Hua" last="Zhong">Hua Zhong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27639429
|texte= Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27639429" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |